A phase II study of sunitinib (Sutent) in patients with muscle-invasive locally advanced TCC [transitional cell carcinoma] of the bladder.
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 14 Jun 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 14 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.